Another phase Ib study evaluated the safety and preliminary antitumor activity of crizotinib plus pembrolizumab (PD-1 inhibitor) as a first-line therapy in patients with ALK+ NSCLC. Here, ALK is linked to non-small cell lung carcinoma.